There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report), Arcus Biosciences (RCUS – Research Report) and Zai Lab (ZLAB – Research Report) with bullish sentiments.
Sarepta Therapeutics (SRPT)
Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on Sarepta Therapeutics on January 21 and set a price target of $145.00. The company’s shares closed last Tuesday at $121.13.
According to TipRanks.com, Schwartz is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $130.56 average price target, representing a 7.3% upside. In a report issued on January 8, Citi also maintained a Buy rating on the stock with a $113.00 price target.
See the top stocks recommended by analysts >>
Arcus Biosciences (RCUS)
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Arcus Biosciences on January 22 and set a price target of $51.00. The company’s shares closed last Tuesday at $15.44.
According to TipRanks.com, Goldstein is a 1-star analyst with an average return of
Currently, the analyst consensus on Arcus Biosciences is a Strong Buy with an average price target of $42.86, representing a 178.1% upside. In a report issued on January 16, Barclays also assigned a Buy rating to the stock with a $35.00 price target.
Zai Lab (ZLAB)
Leerink Partners analyst Jonathan Chang reiterated a Buy rating on Zai Lab on January 19 and set a price target of $62.00. The company’s shares closed last Tuesday at $23.01, close to its 52-week low of $19.88.
According to TipRanks.com, Chang has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zai Lab with a $68.14 average price target, a 197.6% upside from current levels. In a report issued on January 10, Bank of America Securities also maintained a Buy rating on the stock with a $37.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SRPT:
- Sarepta price target raised to $177 from $112 at JPMorgan
- Sarepta initiates screening in EMERGENE study
- Sarepta reports preliminary FY23 net product revenue $1.145B
- Regenxbio: Sarepta granted summary judgment on invalidity in patent suit
- Arcellx named as 2024 Top Pick, added to Conviction List at Needham
